Kenji Yasukawa, Astellas CEO (Akio Kon/Bloomberg via Getty Images)
FDA lifts clinical hold on Astellas’ Pompe gene therapy
The FDA has lifted a clinical hold on Astellas Pharma’s Pompe disease gene therapy trial, the Japanese company announced Friday morning …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
